GlycoMimetics Inc. (GLYC) Financial Statements (2024 and earlier)

Company Profile

Business Address 9708 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41,79347,87190,255137,035158,201209,918
Cash and cash equivalents41,79347,87190,255137,035158,201209,918
Receivables17614412186413
Prepaid expense1,4212,3002739663,8391,609
Other undisclosed current assets401400259271302330
Total current assets:43,79150,71590,789138,273162,528212,269
Noncurrent Assets
Operating lease, right-of-use asset7687511,5762,3253,006
Property, plant and equipment  242369621823957
Prepaid expense604501,5611,5611,5611,561
Other undisclosed noncurrent assets1545252525252
Total noncurrent assets:1,5261,0963,5584,5595,4422,570
TOTAL ASSETS:45,31651,81194,347142,832167,970214,839
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,0947,96210,82311,53010,1468,664
Employee-related liabilities   1,727
Accounts payable8689702,1082,0901,4362,664
Accrued liabilities5,2266,9928,7159,4408,7114,274
Debt     804 
Deferred rent credit      99
Other undisclosed current liabilities7429191,001899  
Total current liabilities:6,8358,88111,82412,42810,9518,763
Noncurrent Liabilities
Long-term debt and lease obligation:   9191,9202,819 
Liabilities, other than long-term debt 67  264 612
Accounts payable and accrued liabilities    264  
Deferred rent credit      612
Operating lease, liability 67 9191,9202,819
Other undisclosed noncurrent liabilities   (919)   
Total noncurrent liabilities: 67 9192,1842,819612
Total liabilities:6,9028,88112,74314,61313,7699,375
Equity
Equity, attributable to parent38,41442,93081,604128,219154,201205,464
Common stock645452494343
Additional paid in capital494,835462,461454,448437,640412,600405,972
Accumulated deficit(456,485)(419,586)(372,897)(309,470)(258,443)(200,551)
Total equity:38,41442,93081,604128,219154,201205,464
TOTAL LIABILITIES AND EQUITY:45,31651,81194,347142,832167,970214,839

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues10751,16010,163  
Gross profit: 10751,16010,163  
Operating expenses(39,285)(47,478)(64,607)(61,672)(61,389)(51,505)
Other undisclosed operating income      
Operating loss:(39,275)(47,403)(63,447)(51,509)(61,389)(51,505)
Loss from continuing operations:(39,275)(47,403)(63,447)(51,509)(61,389)(51,505)
Loss before gain (loss) on sale of properties:(63,447)(51,509)(61,389)(51,505)
Other undisclosed net income2,376715204823,4973,231
Net loss:(36,899)(46,689)(63,427)(51,027)(57,892)(48,274)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(36,899)(46,689)(63,427)(51,027)(57,892)(48,274)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(36,899)(46,689)(63,427)(51,027)(57,892)(48,274)
Comprehensive loss, net of tax, attributable to parent:(36,899)(46,689)(63,427)(51,027)(57,892)(48,274)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: